Miscellaneous Drugs
Last Updated: March 6, 2023
Summary Recommendations Summary Recommendations |
---|
Colchicine- The COVID-19 Treatment Guidelines Panel (the Panel) recommends against the use of colchicine for the treatment of nonhospitalized patients with COVID-19, except in a clinical trial (BIIa).
- The Panel recommends against the use of colchicine for the treatment of hospitalized patients with COVID-19 (AI).
Fluvoxamine- There is insufficient evidence for the Panel to recommend either for or against the use of fluvoxamine for the treatment of COVID-19.
Ivermectin- The Panel recommends against the use of ivermectin for the treatment of COVID-19 (AIIa).
Intravenous Immunoglobulin- The Panel recommends against the use of intravenous immunoglobulin (IVIG) for the treatment of acute COVID-19 in adults and children, except in a clinical trial (AIII). This recommendation should not preclude the use of IVIG when otherwise indicated for the treatment of complications that arise during the course of COVID-19.
- The Panel recommends using IVIG in combination with low to moderate dose glucocorticoids in hospitalized patients for the treatment of multisystem inflammatory syndrome in children (MIS-C) (AIIb).
- The Panel recommends against the routine use of IVIG monotherapy for the treatment of MIS-C unless glucocorticoid use is contraindicated (AIIb).
Metformin- The Panel recommends against the use of metformin for the treatment of COVID-19 in nonhospitalized patients (BIIa) and hospitalized patients (BIII), except in a clinical trial.
- Patients with COVID-19 who are receiving metformin for an underlying condition should continue this therapy as directed by their health care provider (AIII).
|
Each recommendation in the Guidelines receives a rating for the strength of the recommendation (A, B, or C) and a rating for the evidence that supports it (I, IIa, IIb, or III). See Guidelines Development for more information. |